Nicorette OTC use studies meet Waxman/Hatch exclusivity requirements, FDA says.
This article was originally published in The Tan Sheet
Executive Summary
NICORETTE OTC USE STUDIES JUSTIFY WAXMAN/HATCH EXCLUSIVITY for the Rx-to-OTC switch nicotine chewing gum, FDA Center for Drug Evaluation and Research Director Janet Woodcock, MD, says in an Oct. 31 letter to McKenna & Cuneo attorney Gary Yingling. Woodcock's letter responds to a Nov. 2, 1995 petition filed by McKenna & Cuneo asking FDA to deny exclusivity for the OTC smoking cessation gum product ("The Tan Sheet" Nov. 20, 1995, p. 2) and a subsequent petition for stay of action, filed February 16. The petitions were filed on behalf of an undisclosed client.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning